Eventus attracts $2.72M for breast cancer Dx testing and commercial expansion

Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests. They are designed for use along with annual mammograms to spot cancer or determine its absence by measuring ratios of autoantibodies produced in response to tumor-specific antigens. Octava tests have a CE mark and also recently won Israeli regulatory approval. More clinical studies are underway to provide additional data for a U.S. FDA submission. The funding comes from a new family office private investor, plus existing investors. Release

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.